Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL3618 Target Snapshot

Coagulation factor V · SINGLE PROTEIN · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
18Compounds
8Assays
0Approved Drugs
36.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Coagulation factor V shows approved-linked disease relevance led by Multiple Organ Failure. 5 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt P12259. Start with Multiple Organ Failure, then reuse UniProt P12259 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with Multiple Organ Failure, then reuse UniProt P12259 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13 1 linked drug
Open source guide
Disease program
Multiple Organ Failure

Coagulation factor V shows approved-linked disease relevance led by Multiple Organ Failure. 5 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.

Start review with Multiple Organ Failure because it currently carries approved-linked support. Linked drugs include DROTRECOGIN ALFA (ACTIVATED). This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Approved-linked Open Targets-ready proxy 1 linked drug
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Coagulation factor V as ChEMBL target CHEMBL3618, mapped to UniProt P12259. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Coagulation factor V
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL3618
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P12259
Coagulation factor V
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Coagulation factor V is the right protein anchor across sources, using UniProt P12259 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why Multiple Organ Failure is currently framed as approved-linked support. It currently carries 1 linked drug in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameCoagulation factor V
Target TypeSINGLE PROTEIN
OrganismHomo sapiens
UniProtP12259
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelCoagulation factor V
UniProt AccessionP12259
Component TypeProtein
Sequence Length2224 aa

Coagulation factor V

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as Coagulation factor V, mapped to UniProt P12259. Sequence length is 2224 aa.

Mapped IDP12259
Review nameCoagulation factor V
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Approved-linked Open Targets-ready proxy

Coagulation factor V shows approved-linked disease relevance led by Multiple Organ Failure. 5 more disease programs remain visible in the same review block.

Approved-linked Approved
Multiple Organ Failure
1 linked drug · 1 direct · 1 efficacy
Linked drugDROTRECOGIN ALFA (ACTIVATED)
Approved-linked Approved
Recurrent thrombophlebitis
1 linked drug · 1 direct · 1 efficacy
Linked drugDROTRECOGIN ALFA (ACTIVATED)
Approved-linked Approved
Sepsis
1 linked drug · 1 direct · 1 efficacy
Linked drugDROTRECOGIN ALFA (ACTIVATED)
Late clinical Phase III
hypotension
1 linked drug · 1 direct · 1 efficacy
Linked drugDROTRECOGIN ALFA (ACTIVATED)
Late clinical Phase III
Ischemic stroke
1 linked drug · 1 direct · 1 efficacy
Linked drugDROTRECOGIN ALFA (ACTIVATED)
Late clinical Phase III
septic shock
1 linked drug · 1 direct · 1 efficacy
Linked drugDROTRECOGIN ALFA (ACTIVATED)
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with Multiple Organ Failure because it currently carries approved-linked support. Linked drugs include DROTRECOGIN ALFA (ACTIVATED). This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseaseMultiple Organ Failure
Strongest levelApproved-linked
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

1
Phase II
Assay Mix

Activity Type Distribution

IC5029.0
KI7.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL1162108 5.74 IC50 1810.0 Preclinical
CHEMBL259312 5.6 IC50 2500.0 Preclinical
CHEMBL1162109 5.42 IC50 3800.0 Preclinical
CHEMBL410427 5.32 IC50 4800.0 Preclinical
CHEMBL436766 5.24 Ki 5700.0 Preclinical
CHEMBL265687 5.17 IC50 6710.0 Preclinical
CHEMBL410426 5.13 IC50 7400.0 Preclinical
CHEMBL379036 4.89 Ki 13000.0 Preclinical
CHEMBL261865 4.85 IC50 14070.0 Preclinical
CHEMBL1162110 4.85 IC50 14070.0 Preclinical
Distribution

pChEMBL Value Distribution

11
5.0
2
5.5
0
6.0
0
6.5
0
7.0
0
7.5
0
8.0
0
8.5
0
9.0
0
9.5
pChEMBL
Assay Landscape

Assay Landscape

8
Total Assays
20
Tested Compounds
1
Assay Types
Binding — 8 assays, 20 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 6 11 5.0
cell-free format 2 9 4.8

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine